Clinical Trial Update: Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 open-label multicenter trial evaluating isatuximab plus pomalidomide and dexamethasone with carfilzomib in relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Isatuximab (isatuximab)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | Status: UNKNOWN